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Summary Long-term outcome of salvage treatment was reviewed in 67 unselected male patients relapsing
during or after their primary cisplatin-based chemotherapy for metastatic germ cell tumours. Seven patients
underwent only surgery and/or radiotherapy as curatively intended salvage treatment. Thirty-five patients
(52%) had a complete or partial response to salvage treatment, 20 (57%) of whom relapsed again. With a
median follow-up of 90 months (range 3-143 months) 20 patients (30%) are alive with no evidence ofdisease,
15 continuously disease-free and five currently disease-free. The 5 year survival from start of salvage treatment
is 37% for the group as a whole. Multivariate analysis identified age < 35 years, complete response to primary
treatment and a relapse-free interval > 3 months as independent predictors of favourable outcome of salvage
treatment. A group of patients with these good-risk factors (42%) had a 5 year survival of 72% compared
with the remaining patients (58%) with a 5 year survival of only 11%. Whereas patients with good-risk
features may be adequately managed by conventional salvage treatment, the remaining patients carry a very
poor prognosis and require innovative and more aggressive approaches.
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Cisplatin-based combination chemotherapy has considerably
improved the outcome of patients with metastatic germ cell
tumours. Around 75-80% of patients are cured by first-line
treatment. However, 20-25% of patients develop disease
progression during or after their initial chemotherapy and
require effective salvage treatment. The prognosis of the lat-
ter patient group is relatively poor with only 20-30%
disease-free long-term survival (Motzer et al., 1991; Josefsen
et al., 1993; Einhorn et al., 1994).
This retrospective study analyses outcome in patients who
received salvage treatment for refractory or relapsing germ
cell tumours at a single institution. We studied clinical
features and response criteria as prognostic variables predict-
ive of long-term survival after salvage treatment.
Patients and methods
Patient characteristics
Among 433 patients with germ cell tumours treated with
cisplatin-based chemotherapy at Klinikum Grosshadern
between 1979 and 1993, 61 developed signs of relapse during
or after primary treatment. A further eleven patients, who
received their primary treatment elsewhere, were referred to
our institution for treatment of relapse. Relapse was defined
as an increase of serum tumour markers human chorionic
gonadotropin (HCG) and/or a-fetoprotein (AFP) requiring
two samples, a greater than 25% increase of measurable
lesions or development of a new lesion that proved to be
viable cancer. Four patients who relapsed with mature
teratoma or necrotic tumour tissue (one case) were thus
excluded from this study. A further patient was excluded
because of refusal of any salvage treatment. The remaining
67 patients were divided into two risk groups as defined by
Medical Research Council criteria (Mead et al., 1992).
Patients with liver, bone, or brain metastases, a mediastinal
mass > 5 cm, 20 or more lung metastases, AFP > 1000
IU ml-' and/or HCG >10 000 U 1-' constituted a poor-risk
group. Patients without any of these features were considered
as good-risk. Patient characteristics pertaining to status
immediately before initial chemotherapy are summarised in
Table I.
Primary treatment
Up to 1983 all patients received their primary chemotherapy
according to the PVB protocol consisting of cisplatin
20mgm-2 on days 1-5, vinblastine 0.15-0.20mgkg-' on
days 1,2 and bleomycin 30mg on days 2, 9, 16 (Einhorn and
Donohue, 1977). Since 1984 patients with a large tumour
burden have been predominantly treated according to the
ECBC schedule consisting of etoposide 120 mg m 2 on days
1-4, cisplatin 30 mg m2 on days 1-4, bleomycin 15 mg on
day 1 (bolus) and 12mgm2 on days 1-4 (24h infusion),
and cyclophosphamide 300 mg m 2 on days 1-4 (Gerl et al.,
1993a,b). In 1987 we began to treat patients with low-volume
metastatic disease according to the PEB regimen substituting
etoposide 100 mgm2 on days 1-5 for vinblastine (Williams
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1995et al., 1987). Four patients received cisplatin-ifosfamide-
based chemotherapy with either vinblastine (VIP) or
etoposide (EIP) (Table II).
One patient received two cycles of adjuvant chemotherapy
for resected stage II testicular cancer. Only one patient with
unresected low-volume stage II disease received an inad-
equate treatment, since a severe trauma owing to a car
accident led to discontinuation of chemotherapy after two
cycles; nevertheless, primary treatment resulted in a complete
remission (CR). Three patients with stage II disease, who
underwent their primary treatment at other institutions, were
treated with three cycles only, but according to a report of
the Southeastern Cancer Study Group the duration of
chemotherapy had to be regarded as appropriate (Einhorn et
al., 1989). All other patients received at least four courses of
chemotherapy provided they did not develop progressive
disease (PD) earlier during treatment. Patients with large-
volume metastatic disease and very high levels of serum
tumour markers usually received more than four cycles of
chemotherapy (Gerl et al., 1993b). The relative drug intensity
of cisplatin was calculated for an individual patient assuming
that 100mg m2 given within 3 weeks represented the stan-
dard dose (100%) (Longo et al., 1991).
Fifty patients had residual masses at the end of primary
chemotherapy, 28 (56%) of whom were selected for adjunc-
tive surgery after normalisation of serum tumour markers
(Table II). Histology at resection was classified as necrosis/
fibrosis, mature teratoma or viable cancer. Patients who har-
boured viable cancer at post-chemotherapy surgery routinely
received two cycles of adjuvant chemotherapy (Gerl et al.,
1995).
Evaluation ofresponse
Complete response 1 (CR1) was defined as total disapp-
earance of clinical, radiological and biochemical signs of
disease for at least 4 weeks. Patients who had a complete
resection of residual masses containing only necrosis/fibrosis
or mature teratoma also qualified for CR1. CR2 was defined



















































RPLND, retroperitoneal lymph node dissection. See text for other
abbreviations.
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as disappearance of disease after complete resection of viable
cancer. Partial remission was defined as a > 50% reduction
in the sum of the products of the longest perpendicular
diameters of measureable lesions; if elevated markers were
the only evidence of disease, a decrease of 90% or more was
required for a partial response (Loehrer et al., 1988). Prog-
ressive disease (PD) was defined as progression before dis-
continuation of scheduled primary treatment. The prog-
ression-free interval was defined as the time span between
CR, PR or stable disease at the end of primary chemo-
therapy and the diagnosis of relapse. Primary chemotherapy
resistance was defined as PD during primary chemotherapy,
or within 4 weeks after discontinuation of treatment.
Salvage treatment
Salvage chemotherapy was applied according to the VIP
regimen consisting of vinblastine 6 mg m 2 on days 1 and 2,
ifosfamide 1.5 gm2 on days 1-5 and cisplatin 20mgm2
on days 1-5 (Clemm et al., 1982) with gradual shift to the
EIP schedule substituting etoposide for vinblastine (Table
III). Since 1984 11 patients have received salvage chemo-
therapy according to the ECBC schedule (Gerl et al.,
1993a,b). Three patients were treated with other cisplatin-
based regimens, and four patients received non-cisplatin-
containing protocols. The majority of patients received 3-4
courses of salvage chemotherapy depending on the course of
disease and toxicity. Dose reductions were performed as
indicated by clinical, haematological or renal toxicity. Four
Table III Patient characteristics at start of salvage treatment and
outcome of second-line chemotherapy
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patients underwent high-dose chemotherapy with autologous
bone marrow rescue; two patients received a regimen consis-
ting of etoposide and cyclophosphamide, while the other two
patients were treated with carboplatin-based protocols.
Seven patients did not receive any salvage chemotherapy.
One patient with Friedreich's ataxia who relapsed with a
retroperitoneal mass and increasing AFP 3 years after dis-
continuation of primary treatment was successfully salvaged
by surgery alone. Six patients who had an isolated cerebral
relapse were treated by surgery and subsequent whole brain
irradiation or radiotherapy alone (one patient) (Gerl et al.,
1994).
Overall 35 patients underwent surgery at some stage during
their salvage treatment. Retroperitoneal lymph node dissec-
tion (RPLND) was performed in 21 patients, thoracotomy in
seven and craniotomy in eight. Fourteen of these 35 patients
(40%) had already undergone surgical interventions as part
of their primary treatment. In patients with marker negative
relapses surgery was routinely undertaken as first salvage
treatment in order to recognise disease reactivation with
mature teratoma only. Furthermore, some heavily pretreated
patients with localised disease that was deemed resectable
were referred to surgery as first salvage modality.
Of 60 patients 42 (70%) had residual masses after salvage
(second-line) chemotherapy. Nine of these 42 patients (21%)
were referred to surgery. Five of these nine patients had
normal tumour markers and three of them harboured viable
cancer; the remaining four patients had elevated tumour
markers and all harboured viable cancer.
Overall 15 patients who had chemorefractory disease or
who relapsed after at least two chemotherapy regimens
underwent surgical salvage as defined elsewhere (Murphy et
al., 1993). Eleven of these 15 patients underwent RPLND as
salvage surgery, four patients thoracotomy; serum HCG was
elevated in eight patients before salvage surgery, AFP in
seven.
Twenty-seven patients underwent radiotherapy as part of
their salvage treatment, most often given with palliative
intention. Of the 27 patients 18 had whole-brain irradiation
for cerebral metastases.
Follow-up
Patients with a CR to salvage treatment underwent clinical,
radiological and biochemical examinations at 3 months dur-
ing the first 2 years and at 6 month intervals during the third
year, thereafter annually. Survival was taken from start of
salvage treatment to death or the most recent visit to the
hospital. Median follow-up of surviving patients was 90
months (range 3-143 months).
Statistical analysis
Survival distributions were estimated by the Kaplan-Meier
method, and comparative survival of subgroups was deter-
mined by the log-rank test. Univariate variables (Table IV)
included period ofdiagnosis and pretreatment patient charac-
teristics: age at diagnosis, primary site and tumour burden as
defined by three different staging systems (Loehrer et al.,
1988; Hitchins et al., 1989; Mead et al., 1992). Further
univariate comparisons included factors related to primary
treatment: vinblastine- vs etoposide-containing chemother-
apy, relative dose intensity ofcisplatin, response, and relapse-
free interval. Univariate analyses were also performed ac-
cording to patient characteristics at relapse: tumour burden
as defined by number of metastatic sites, presence or absence
of pulmonary metastases and tumour marker status. Mul-
tivariate analysis was performed using a forward stepwise
selection procedure with P <0.05 as an entry criterion.
Results
Diagnosis ofrelapse
In 31 patients the first sign of relapse was an increase of
serum HCG and/or AFP. Nineteen patients showed an inc-
rease of pre-existent masses, while 17 developed new lesions.
Patient characteristics pertaining to the status at the start of
salvage treatment are summarised in Table III.
The median progression-free interval was only 3 months
(range 0 - 105 months). In 14 patients more than 12 months
elapsed after discontinuation of primary treatment. Primary
chemotherapy resistance was observed in 22 patients.
Response and toxicity
Second-line treatment led to a CR in 24 patients (36%) and
to a PR in 11 patients (16%) (Table III). In 20 of these 35
patients (57%) disease reactivated during or after salvage
therapy with a median of 5 months from start of salvage
treatment (range 1-80 months). None of the four patients
who underwent high-dose chemotherapy achieved a durable
response.
Third-line chemotherapy was given to 29 patients. Three of
the 29 patients (10%) attained a CR and are currently alive
with no evidence of disease (NED) status 6, 17 and 104
months after initiation of third-line chemotherapy.
Myelosuppression frequently led to delay or modifications
of salvage chemotherapy. During the last 3 years growth
factors were applied in some patients to enable the administ-
ration of sufficient doses at short intervals. One patient died
from neutropenic septicaemia after third-line chemotherapy;
there was evidence of active disease.
Three of the six patients who underwent a craniotomy and
subsequent radiotherapy for an isolated cerebral relapse are
alive with NED status 29, 88 and 92 months after start of
salvage treatment. A further patient who received whole-
brain irradiation and chemotherapy for cerebral metastases
developed a glioblastoma after 115 months and is currently
alive with this second malignancy.
Three of the 15 patients who underwent salvage surgery
for chemorefractory disease are disease-free survivors at 38,
53 and 92 months after surgery. Salvage surgery was a
RPLND in these three cases with a presurgical elevation of
HCG in two patients and of AFP in one case.
Survival
Overall survival from the beginning of salvage treatment is
shown in Figure 1. At the end of the observation time 20
patients (30%) are alive with NED status, 15 continuously
disease free after second-line treatment and five after further
treatment. Four additional patients are alive with disease and
currently receive third-line treatment. Forty-three patients
died with a median of 9 months after start of salvage treat-
ment. Of these 43 patients 40 died within 2 years, whereas
three patients survived for 65, 91 and 107 months respect-
ively.
Of the pretreatment factors age < 35 years, testicular
origin and low-volume metastatic disease as defined by three
different staging systems were associated with favourable
long-term outcome (Table IV). In contrast, the use of
vinblastine- or etoposide-containing regimens and the relative
drug intensity ofcisplatin did not affect outcome. However, a
CR to primary treatment and a relapse-free interval >3
months predicted a favourable prognosis after salvage treat-
ment. Low-volume metastatic disease and absence of pul-
monary metastases at start of salvage treatment were also
associated with favourable long-term outcome. Serum
tumour marker status before salvage treatment was not of
prognostic relevance.
Multivariate analysis identified age < 35 years, CR to
primary treatment and a relapse-free interval >3 months as
independent predictors of favourable outcome (Table V).
These factors were used to define a simple prognostic model.
Patients with only good-risk factors (n = 28, 42%) had a 5
year survival of 72% (95% confidence interval 54-90%),
whereas patients with at least one poor-risk factor (n = 39,
58%) (age >35 years, <CR2 to primary treatment, relapse-
free interval < 3 months) had a 5 year survival of only 11%
(95% CI 0-22%) (Figure 2).
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1028It is important to stress that initial tumour burden was a
highly significant parameter in univariate comparisons, but it
lost its significance in the multivariate model after entry of
the variable response. For example, five of ten patients desig-
nated poor risk by MRC criteria but good risk by our model
were alive. Conversely, only two of seven patients designated
good risk by MRC criteria but poor risk by our model
survived. Table VI summarises the clinical course of 18
patients with at least 12 months disease-free survival after
discontinuation of salvage treatment. Twelve of these 18
patients had an isolated relapse at the retroperitoneal space.
Discussion
Testicular cancer is one of the few neoplasms for which
second-line or even third-line therapy can lead to CR. Forty-
five per cent of patients can attain disease-free status with
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Figure 1 Survival from the beginning of salvage treatment for 67
patients relapsing during or after primary therapy. Eighteen
patients remain at risk at 60 months.




































Variables at start ofsalvage treatment
No. of metastatic sites































































aSee text and Mead et al., 1992. bSee Loehrer et al., 1988.CSee Hitchins et al., 1989.
Low markers: HCG < 50 000 U 1-' and AFP < 500 IUml-'. High markers:
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chemotherapy (Einhorn et al., 1994). Similar CR rates can be
achieved with other salvage regimens (Ledermann et al.,
1994). Unfortunately, about one-half of the patients with CR
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Figure 2 Survival from the beginning of salvage treatment by
prognostic group: good prognosis (n = 28, 42%), no poor-risk
factor (- - - -); poor prognosis (n = 39, 58%), at least one
poor-risk factor (age>35 years, incomplete response to primary
therapy, relapse-free interval < 3 months).
disease-free long-term survival between 20% and 30%
(Harstrick et al., 1991; Motzer et al., 1991; Josefsen et al.,
1993; Einhorn et al., 1994). The 30% disease-free survival
rate at a median follow-up of 90 months observed in our
study is thus comparable to the results of other authors and
stresses the need for continued investigation of potentially
more efficacious salvage treatment.
Apart from second-line chemotherapy surgery plays an
important role as part of salvage treatment. In patients with
marker negative relapses surgery should be the first salvage
procedure to recognise regrowth with mature teratoma which
is adequately treated by surgery alone (Jansen et al., 1991).
Differential diagnosis of marker negative relapse also
includes second malignancy as observed in one of our
patients who developed a glioblastoma more than 9 years
after whole-brain irradiation for cerebral metastases. Patients
with normal tumour markers but residual masses after
second-line chemotherapy should undergo resection whenever
feasible, as the chance of harbouring viable cancer is over
50% (Fox et al., 1993). Moreover, surgery has a small but
definite curative potential in chemorefractory resectable
disease (Cassidy et al., 1992; Murphy et al., 1993). Three of
15 patients (20%) with this condition were disease-free long-
term survivors in our study. Patients with a single cerebral
metastasis and no evidence of disease at other sites under-
went surgical removal and subsequent whole brain irradiat-
Table V Result of multivariate analysis
Variable Chi-square Degree offreedom P
CRI, CR2 vs <CR2 31.0 1 <0.001
Age <35 vs >35 years 4.5 1 0.034
Interval < 3 months 3.5 1 0.062
vs >3 months
All three variables 43.4 3 <0.001
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14 IV/G L PVB/Thoracotomy
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is probably treatment related. G, good-risk; P, poor-risk; R, retroperitoneum; L, lung; M, mediastinum; C, cervical
nodes; Br, brain; B, bone; Mar, marker elevation only. See text for other abbreviations.
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ion. Three of six patients with this condition survived disease
free (Gerl et al., 1994).
To overcome drug resistance high-dose chemotherapy with
autologous bone marrow or peripheral stem cell rescue has
been evaluated by several investigators. However, using high-
dose chemotherapy as third-line treatment clinical outcome is
disappointing with only 15-20% long-term disease-free sur-
vival (Einhorn et al., 1994; Siegert et al., 1994). More
encouraging results have been reported for patients treated
with high-dose chemotherapy at an earlier stage (Barnett et
al., 1993; Broun et al., 1994; Siegert et al., 1994). However, at
present there is no consensus about inclusion criteria. If all
patients with poor-risk features as defined by the largest
prognostic factor analysis (Mead et al., 1992) were selected
for high-dose chemotherapy as first-line treatment, approx-
imately two-thirds of patients would receive a toxic and
costly overtreatment. Whereas one group of investigators
used a prolonged serum tumour marker decline during the
first two courses of primary chemotherapy as selection
criterion for early intervention with high-dose chemotherapy
(Motzer et al., 1992), two recent reports could not substan-
tiate the prognostic importance of early serum tumour
marker half-life (Gerl et al., 1993a; Stevens et al., 1995).
Therefore, search for appropriate treatment-related variables
which complement pretreatment risk stratification has to be
continued.
Looking at pretreatment prognostic variables in our study,
age >35 years, extragonadal origin and large-volume metast-
atic disease as defined by three different staging systems
predicted poor prognosis after salvage treatment. The last
two parameters were identified by other investigators (Motzer
et al., 1991; Droz et al., 1993; Saxman et al., 1994), but these
variables lost their prognostic relevance in our multivariate
model. Although age has been identified as a prognostic
factor in two studies including large numbers ofpatients with
non-seminomatous germ cell tumours (Aass et al., 1991;
Mead et al., 1992), its relevance in predicting outcome of
salvage treatment has not been reported previously.
In agreement with other reports a CR to primary treat-
ment was identified as most important predictor of favour-
able outcome of salvage treatment (Harstrick et al., 1991;
Motzer et al., 1991; Pizzocaro et al., 1992; Droz et al., 1993).
As described by several investigators the prognostic relevance
of the relapse-free interval was substantiated by our study
(Horwich et al., 1993; Josefsen et al., 1993; Steyerberg et al.,
1993; Gerl et al., 1995), although it reached only borderline
significance in our multivariate model.
As in previous reports tumour burden at start of salvage
treatment was correlated to long-term outcome (Loehrer et
al., 1988; Motzer et al., 1991; Horwich et al., 1993). Patients
with marker elevation only or one site of disease fared
markedly better than patients with two or more sites of
metastatic spread. In concordance with other investigators we
found that presence of pulmonary metastases at start of
salvage treatment was an adverse prognostic factor (Droz et
al., 1993).
Multivariate analysis identified age <35 years, CR to
primary treatment and a relapse-free period of more than 3
months as independent prognostic variables predictive of
favourable outcome of salvage treatment. These prognostic
factors allowed us to define a subgroup ofpatients who fared
relatively well with conventional salvage treatment as shown
by a 5 year survival rate of 72%. The remaining patients had
a 5 year survival of only 11%. The division into good and
poor prognostic groups is easily applied. However, as our
study included only 67 patients, the general applicability of
the results is limited to a certain degree (Simon and Altman,
1994). The validity of our model should be tested on an
independent data set.
Our model defines a subgroup of patients at diagnosis of
relapse who have only a very small chance of being cured by
conventional salvage treatment. Applying our model these
patients could avoid the cumulative toxicity of unsuccessful
conventional salvage chemotherapy. Moreover, these patients
might benefit from early intervention with high-dose chemo-
therapy because ofa potentially lower level ofdrug resistance
compared with patients receiving high-dose chemotherapy at
second relapse.
Although pretreatment tumour burden did not enter our
multivariate model, it is important to emphasise that MRC
criteria and the Indiana University staging system were
almost as useful as our model in predicting outcome after
salvage treatment in our study population. However, our
results showed that patients presenting with poor-risk
features according to MRC criteria but being good risk
according to our model fared relatively well. Conversely,
patients presenting with good-risk features by MRC criteria
but designated as poor-risk by our study had a relatively
poor prognosis. However, conclusions have to be drawn with
caution, since patients with the aforementioned character-
istics represented only a small proportion of the entire study
population.
In conclusion, we defined a simple prognostic model
distinguishing patient groups highly likely and unlikely to be
cured by conventional salvage treatment. This model includes
response criteria as prognostic variables and might be useful
for selecting patients for high-dose chemotherapy at diag-
nosis of first relapse. However, the validity of our model
should be tested on an independent data set, and a clear
advantage over prognostic models using only pretreatment
characteristics remains to be defined.
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